Tranilast inhibits TGF-β-induced collagen gel contraction mediated by human corneal fibroblasts

Ye Liu¹, Xiao-Jing Zhao², Xiao-Shuo Zheng², Hui Zheng², Lei Liu¹, Ling-Bin Meng¹, Qin Li², Yang Liu²

¹Department of Pathology, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, Guangdong Province, China
²Department of Ophthalmology, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, Guangdong Province, China
³Department of Ophthalmology, the First Hospital of Jilin University, Jilin 130021, Jilin Province, China
⁴Department of Internal Medicine, Florida Hospital, Orlando, Florida 32803, USA

Correspondence to: Yang Liu. Department of Ophthalmology, the Fifth Affiliated Hospital of Sun Yat-sen University, 52 Road Meihuadong, Zhuhai 519000, Guangdong Province, China. liuyang26@mail.sysu.edu.cn

Received: 2018-04-13 Accepted: 2018-05-31

Abstract

● AIM: To determine if tranilast affects human corneal fibroblast (HCFs) contraction.
● METHODS: HCFs cultured in a three-dimensional type I collagen gel were treated with or without transforming growth factor beta (TGF-β) or tranilast. Gel diameter was measured as an indicator for collagen contraction. Immunoblot was performed to evaluate myosin light chain (MLC) and paxillin phosphorylation. Confocal microscopy was employed to examine the focal adhesions and actin stress fiber formation. Immunoblot analysis and gelatin zymography were performed to detect tissue inhibitors of metalloproteinases and matrix metalloproteinases (MMPs) in supernatant.
● RESULTS: The inhibitory effect of tranilast on HCFs-mediated collagen gel contraction induced by TGF-β was dose-dependent. The significant effect of tranilast was started from 100 μmol/L and maximized at 300 μmol/L. The peak effect of 300 μmol/L tranilast also relied on the duration of treatment, which showed statistical significance from day 2. TGF-β-induced paxillin and MLC phosphorylation, stress fiber formation, focal adhesions, and MMP-1, MMP-2, and MMP-3 secretion in HCFs were also inhibited by tranilast.
● CONCLUSION: Tranilast suppresses the HCFs-cultured collagen gel contraction induced by TGF-β. It attenuates actin stress fibers formation, focal adhesions, and the secretion of MMPs, with these actions likely contributing to the inhibitory effect on HCF contractility. By attenuating the contractility of corneal fibroblasts, tranilast treatment may inhibit corneal scarring.

● KEYWORDS: tranilast; transforming growth factor beta; corneal fibroblast; corneal wound healing

DOI:10.18240/ijo.2018.08.01


INTRODUCTION

The cornea is a transparent tissue. Corneal scarring that results from trauma, mechanical injury, infection, or surgery is a leading cause of blindness worldwide, affecting a total of 7 to 10 million people[1]. Corneal transplantation remains the standard strategy for corneal blindness therapy. However, the clinical reach of corneal transplantation is limited by the supply of donor corneas, and its effectiveness can be compromised by postsurgical complications such as graft failure and rejection[2]. There are currently no effective topical treatments for corneal scarring, and the development of new therapies is thus a clinical priority. More than 90% of the total cornea is composed of stroma. The current theories regard the corneal stroma as being primarily responsible for the transparency of the cornea. Stromal injury may lead to wound healing. This healing is essentially a series reactions at the cellular and biochemical levels that are characterized by inactive fibroblast activation, migration, and proliferation, as well as extracellular matrix (ECM) synthesis and contraction[3]. However, corneal scarring, a severe complication of corneal injury, could be caused by inordinate stroma contraction at the wound site. Previous studies showed that transforming growth factor beta (TGF-β) significantly affects corneal fibrosis and scarring[4-5], with TGF-β signal transduction thus being a promising target of developing anti-fibrotic therapies. The disruption of TGF-β signaling by the targeted delivery of the inhibitory protein Smad7 with a recombinant adeno-associated virus injected into the corneal stroma has been found to attenuate the incidence of corneal haze after photorefractive keratectomy (PRK) in a rabbit model of corneal injury[6]. Treatment with cationic nanoparticles...
complexed with a combination of three small interfering RNAs targeting TGF-β and its receptor mRNAs also inhibited the occurrence of corneal haze in an in vitro model of rabbit cornea culture[7].

Tranilast, or N-(3’4’-dimethoxy-cinnamoyl)-anthranilic acid, is used as an anti-allergic medicine that is widely applied for the administration in allergic diseases (e.g. allergic conjunctivitis, bronchial asthma, and hypertrophic scars)[8]. It also exerts an anti-fibrotic effect by inhibiting TGF-β functions. Tranilast attenuated the development of diabetic dysfunction and histopathological characteristics of experimental diabetic cardiomyopathy by inhibiting TGF-β-induced protein kinase phosphorylation[9]. The topical application of tranilast was also shown to attenuate the development of corneal haze after PRK[10] and to prevent postoperative adhesion after strabismus surgery[11] in rabbit models by suppressing TGF-β expression.

Given that corneal fibroblast-mediated collagen contraction is involved in corneal scarring and the loss of corneal transparency, using an in vitro model, we investigated if tranilast has effects on human corneal fibroblast (HCF)-mediated collagen gel contraction in stimulation with TGF-β. Moreover, we tested the effects of tranilast on myosin light chain (MLC) and paxillin phosphorylation, the secretion of tissue inhibitors of metalloproteinases (TIMPs) and matrix metalloproteinases (MMPs), as well as the development of focal adhesions and actin stress fibers in these cells.

**MATERIALS AND METHODS**

**Materials**

The materials and abbreviations of the companies that supplied the materials are listed as follows. Invitrogen-Gibco (Rockville, MD, USA): fetal bovine serum (FBS), trypsin-EDTA, and 10× Eagle’s minimum essential medium (MEM). Nacalai Tesque (Kyoto, Japan): bovine serum albumin (BSA). Nitta Gelatin (Osaka, Japan): reconstitution buffer for overnight. Then, the membrane was washed extensively with Tris-buffered saline with Tween-20. Horseradish peroxidase-conjugated secondary antibodies were incubated at room temperature for one hour and detected by ECL reagents. The intensity of the immunoreactive bands was measured by ImageJ (NIH, Bethesda, MD, USA).

**Gelatin Zymography**

According to the previous study, gelatin zymography for culture supernatants was performed[14]. A mixture of culture supernatant (8 μL) and nonreducing SDS sample buffer (4 μL) were applied to SDS-PAGE (0.1% gelatin) at 4°C. The gel then went through the following process: primary incubation in 2.5% Triton X-100 at room temperature for 1h, secondary incubation in a reaction buffer of 1% Triton X-100, Tris-HCl (50 mmol/L), and CaCl₂ (5 mmol/L) for 18h at 37°C, and final staining with 0.5% Coomassie brilliant blue.

**Fluorescence Microscopy**

According to a described protocol, F-actin staining and phosphotyrosine of HCFs cultured in...
collagen gel were performed. Fixation of HCFs in collagen gels were performed by applying 1% paraformaldehyde in phosphate-buffered saline (PBS) for half an hour at room temperature, allowed to dry, and then permeabilized by 1% Triton X-100 in PBS for another half hour. After 1% BSA blocking, the cells were incubated for 1h with anti-phosphotyrosine (1:200 dilution) antibody at room temperature and then incubated with Alexa Fluor 488-conjugated secondary antibody (1:1000 dilution) for a half hour. Finally, the cells were incubated with 1:200 diluted phalloidin (Alexa Fluor 568-conjugated) for a half hour for F-actin staining and incubated with 1:3000 diluted TOTO-3 iodide for 10min for nuclei staining. A confocal scanning laser microscope (Axiovert200M; Carl Zeiss, Japan) was used for imaging.

**Statistical Analysis** Quantitative data are expressed as means±standard deviation (SD). The experiments were performed at least three times (triplicated for each independent experiment). Significant differences were determined using Dunnett’s multiple comparison test or the Tukey-Kramer test. A significant level of $P$ value of 0.05 was used for all statistical tests.

**RESULTS**

**Effect of Tranilast on Human Corneal Fibroblasts-mediated Collagen Gel Contraction Induced by TGF-β** To investigate if tranilast can affect collagen contraction mediated by HCFs, we employed a three-dimensional collagen gel for cell culture with or without 1 ng/mL of TGF-β as well as several concentrations of tranilast for various durations. In our 3-day incubation with tranilast at a range of 30 to 300 μmol/L, the inhibition of TGF-β-stimulated gel contraction by tranilast was dose-dependent. We observed a statistically significant effect that started from 100 μmol/L and maximized at 300 μmol/L (Figure 1). This effect of 300 μmol/L tranilast was also duration-dependent and became statistically significant at day 2 (Figure 2).

**Effects of Tranilast on TGF-β-induced Stress Fibers and Focal Adhesion Formation in Human Corneal Fibroblasts** The 3-day cell culture in collagen gels with no TGF-β contained no stress fibers and exerted a dendritic morphology and few phosphotyrosine-specific fluorescence signals (Figure 3A-3C). Cells cultured with TGF-β exhibited actin stress fibers accompanied with phosphotyrosine immunofluorescence in a punctate pattern. The merged fluorescence signal of F-actin and phosphotyrosine implied that stress fiber formation may correlate with phosphotyrosine expression (Figure 3E-3G). However, compared with cells only stimulated by TGF-β, the group exposed to TGF-β and treated with 300 μmol/L of tranilast showed a relatively normal morphology with less stress fiber formation and focal adhesions (Figure 3I-3K). The negative control of normal mouse IgG staining confirmed the specificity of phosphotyrosine staining (Figure 3D, 3H).

**Effects of Tranilast on the Secretion of MMPs and TIMPs by Human Corneal Fibroblasts** Immunoblot analysis...
revealed that TGF-β increased the release of MMP-1 and MMP-3 in culture. The secretion of these proteins was sensitively and dose-dependently inhibited by tranilast. In supernatant gelatin zymography, the amounts of the pro and active forms of MMP-2 were significantly increased by TGF-β. However, the effect was suppressed by tranilast at 300 μmol/L. TGF-β minimally stimulated the release of TIMP-2 from HCFs, which was not inhibited by tranilast (Figure 6).

**DISCUSSION**

The current study revealed that tranilast inhibited the HCFs-mediated collagen gel contraction induced by TGF-β in a dose- and duration-dependent manner. Tranilast also attenuated TGF-β-stimulated paxillin and MLC phosphorylation, as well as focal adhesion and stress fiber formation. In addition, tranilast inhibited the secretion of MMP-1, MMP-2, as well as MMP-3 by HCFs stimulated by TGF-β.
Cornea transparency is largely contributed by the stroma, which consists of ECM (mainly type I collagen) and keratocytes. Contraction mediated by HCFs is required for wound closure during the normal wound healing process [15]. However, excessive contraction may result in the development of corneal scarring and the consequent loss of tissue clarity. Floating three-dimensional collagen gels have been adopted as a model for studies of fibrosis and tissue contractility. TGF-β plays a crucial role in corneal fibrosis. In the current study, we demonstrated that tranilast alleviated the contraction of collagen gel under the stimulation of TGF-β, which was mediated by HCFs with dose- and duration-dependent characteristics. Corneal haze after photorefractive keratectomy can be inhibited by topical tranilast through down-regulating TGF-β1 expression in keratocytes [10]. Additionally, 0.5% tranilast ophthalmic solution instillation was effective in preventing adhesion and fibrosis after strabismus surgery [11]. The present results implied that tranilast could also effectively prevent or treat corneal scarring through its inhibitory action on the contractility of corneal fibroblasts.

Figure 5 Inhibitory effect of tranilast on MLC phosphorylation in HCFs induced by TGF-β

A: Multiple doses of tranilast were applied to cells seeded in collagen gels for 6h, followed by a 3-day incubation with or without 1 ng/mL TGF-β. Cell lysates were incubated with anti-phosphorylated (p-) antibody or MLC for immunoblot analysis. β-actin was set as the internal control. B: Quantitation of the ratio of p-MLC or total MLC to β-actin for cells with the same treatment. Data are presented as means±SD. Dunnett’s test was used for the data analyses. *P<0.05 compared with the corresponding value of cells incubated without the addition. †P<0.05 compared with the corresponding value of cells incubated with TGF-β only.

Figure 6 Inhibitory effect of tranilast on the secretion of MMPs and TIMPs by HCFs

A 3-day cell incubation was performed in collagen gels with or without 1 ng/mL TGF-β and with the labeled doses of tranilast. The culture supernatants were then used for immunoblot analysis with anti-MMP-1, anti-MMP-3, anti-TIMP-1, or anti-TIMP-2 antibodies and analyzed by gelatin zymography for detecting pro and active forms of MMP-2.

Corneal transparency is largely contributed by the stroma, which consists of ECM (mainly type I collagen) and keratocytes. Contraction mediated by HCFs is required for wound closure during the normal wound healing process [15]. However, excessive contraction may result in the development of corneal scarring and the consequent loss of tissue clarity. Floating three-dimensional collagen gels have been adopted as a model for studies of fibrosis and tissue contractility. TGF-β plays a crucial role in corneal fibrosis. In the current study, we demonstrated that tranilast alleviated the contraction of collagen gel under the stimulation of TGF-β, which was mediated by HCFs with dose- and duration-dependent characteristics. Corneal haze after photorefractive keratectomy can be inhibited by topical tranilast through down-regulating TGF-β1 expression in keratocytes [10]. Additionally, 0.5% tranilast ophthalmic solution instillation was effective in preventing adhesion and fibrosis after strabismus surgery [11]. The present results implied that tranilast could also effectively prevent or treat corneal scarring through its inhibitory action on the contractility of corneal fibroblasts.

Cell contractility has been reported to be enhanced by TGF-β stimulation. The mechanisms include focal adhesion activation and actin microfilaments polymerization and reorganization [13]. Another study showed that actin stress fibers formation and the activation of adhesion molecules related to integrin-ECM interactions could contribute to the contraction of collagen gel mediated by HCFs [12]. We have now shown that TGF-β-stimulated actin stress fibers and focal adhesion formation in HCFs can be inhibited by tranilast. By activating both serine-threonine and tyrosine kinases signaling pathways, TGF-β induces downstream molecule phosphorylation [16]. Paxillin, a focal adhesions component, takes tyrosine phosphorylation under the TGF-β stimulation [17]. The phosphorylation of MLC further enhances stress fiber formation as well as actomyosin contraction [18]. Based on our current data, we demonstrated that tranilast suppressed TGF-β-induced paxillin and MLC phosphorylation in HCFs cultured in collagen gels. Thus, partly due to the inhibition of paxillin and MLC phosphorylation, tranilast alleviated the focal adhesion formation and stress fibers induced by TGF-β. The effects of tranilast could also inhibit the fibrotic tissue contraction in corneal scarring. TGF-β induces fibrosis both by eliciting cellular transdifferentiation and modulating MMP activity [19]. MMPs are calcium-dependent zinc-containing endopeptidases. They can target the ECM components to up-regulate the expression of the enzymes that are associated with inordinate scarring at the ocular surface [20]. MMPs have been proven to be involved in wound contraction and matrix reorganization. They have exhibited important
Tranilast inhibition of corneal fibroblast contraction functions during wound healing\(^{[21-22]}\). An animal study showed that the inhibition of MMPs could reduce matrix contraction and limit subconjunctival scarring\(^{[23]}\). Various studies have also demonstrated that TGF-β up-regulates MMP-1, MMP-2, and MMP-3 expression\(^{[14,24-25]}\). We found that tranilast attenuated the release of these MMPs in HCFs induced by TGF-β, implying that the inhibiting effects of tranilast on TGF-β-induced collagen gel contraction could also be caused by similar mechanisms.

In summary, we have shown that tranilast inhibited the HCF contraction induced by TGF-β by suppressing actin stress fibers formation, focal adhesions formation, and MMPs release. Therefore, tranilast may effectively inhibit corneal scarring by attenuating corneal fibroblast contractility.

ACKNOWLEDGEMENTS

Foundations: Supported by the National Science Foundation of China (No.81770889); the Natural Science Foundation of Guangdong Province (No.2017A030313774); the Research Fund of Jilin Provincial Science and Technology Department to Yang Liu (International Cooperation Item, No.20160414055GH).

Conflicts of Interest: Liu Y, None; Zhao XJ, None; Zheng XS, None; Zheng H, None; Liu L, None; Meng LB, None; Li Q, None; Liu Y, None.

REFERENCES